Posters
Comparison of safety and efficacy of local nonsteroidal anti-inflammatory drugs and corticosteroids in common cataract surgery patients
Poster Details
First Author: M.Hlozanek CZECH REPUBLIC
Co Author(s): K. Hlozankova A. Klezlova P. Studeny
Abstract Details
Purpose:
To compare the safety and efficacy of application of two different local nonsteroidal anti-inflammatory drugs (NSA) - nepafenac and indomethacine eye drops, and dexamethasone eye drops perioperatively in patients undergoing the cataract surgery.
Setting:
Clinic of Ophthalmology, University Hospital Kr�Ã�¡lovsk�Ã�© Vinohrady, Prague, Czech Republic
Methods:
Seventy five healthy patients planned for cataract surgery of both eyes were enroled to the study. Each patient randomly obtained double blinded medication to randomly chosen eye, prescribed t.i.d. one day before surgery, once at the surgery day and t.i.d. following surgery. Study medication contained eather nepafenac 1mg/ml, indomethacine 0.1% or dexamethasone 0.1% (3x25 pieces). The fellow eye was treated in standard regime (dexamethasone 0.1% 5 drops daily after surgery). Following parameters were evaluated: anterior chamber inflammation, intraocular pressure, presence of macular oedema, peroperative pain. Follow-ups were performed at day 1, week 1, month 1, 3 and 6 after surgery
Results:
Study was finished by 68 patients. No significant difference was observed in anterior chamber inflammation and intraocular pressure. Peroperative pain was low in all patients, however triple higher in dexamethasone group compared with both NSA groups. As for macular oedema, none was registered in NSA groups, 2 were observed in dexamethasone group (9.5%) and 5 were diagnosed in group of fellow eyes (7.4%).
Conclusions:
Perioperative treatment with NSA was save and efficient in our study. NSA reduced peroperative pain more effectively than dexamethasone, as well as the risk of postoperative macular oedema. We didn�Â�´t observe any important difference between nepafenac and indomethacine group in evaluated parameters.
Financial Disclosure:
NONE
